# Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

> **NCT02859064** · PHASE2 · TERMINATED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 6 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Gastrointestinal Neoplasms
- Carcinoid Tumors

## Interventions

- **DRUG:** Lanreotide
- **DEVICE:** Y-90 microspheres

## Key facts

- **NCT ID:** NCT02859064
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-28
- **Primary completion:** 2022-05-27
- **Final completion:** 2022-06-10
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Closed due to slow accrual
- **Last updated:** 2023-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02859064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02859064, "Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02859064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*